these analyses involve complex and time-consuming procedures.
ESFT are associated with specific chromosomal translocations, which are correlated with the presence of specific chimeric genes. These chimeric genes are considered to play an important role in tumorigenesis and the mechanisms of malignancy in ESFT. The best-known chromosomal translocation in ESFT is t (11; 22), 4) and the EWS-FLI1 chimeric gene is generated through this translocation. Other chimeric genes in ESFT are EWS-ERG, EWS-ETV1, EWS-E1AF, and EWS-FEV, which are generated from the chromosomal translocations t (21; 22), 5, 6) t (7; 22), 7) t (17; 22), 8) and t (2; 22), 9) respectively. The partners of these chimeric genes (FLI1, ERG, ETV1, E1AF, and FEV) are members of the ETS gene family, whose products function as transcription factors. 10) Moreover, these ETS gene family members generate chimeric genes by using different parts of exons. [11] [12] [13] Here, we describe much more easy and simultaneous detection for these chimeric genes in ESFT and its clinical applications.
MATERIALS AND METHODS

Cell Lines
We examined three ES cell lines (NCR-EW2, 12) SCMC-ES-1, 13) and KP-EW-MS 13) ), two PNET cell lines (SK-N-MC 13) and SK-N-L0 13) ), and one NB cell line (IMR-32). The chimeric gene detected for each cell line is shown in Table 1 . IMR-32 has no chimeric gene, so we used it as a negative control. All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 g/l sodium bicarbonate, then incubated in 5% CO 2 at 37°C. RNA Extraction Total RNA was extracted from cultured cells with TRIZOL reagent (GIBCO BRL), based on the acid guanidinium-phenol-chloroform method. 14) Primer Design We designed all primers from outside sequence of break points on the genes, which compose chimeric genes. So we can detect all chimeric genes, which have been recognized in ESFT (Fig. 1) .
RT-PCR and PCR Products Analysis cDNA was generated by using ReverTra Ace -a-(TOYOBO) from 0.8 mg of total RNA in a 10 ml reaction mixture. mRNA Selective PCR Kit Ver. 1.1 (TaKaRa) was used for PCR, which was 
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performed in 10 ml of reaction mixture containing 1.2 pmol of all primers, as summarized in Table 2 . 8, 12, 15) The amplification step was preformed in a TaKaRa PCR Thermal Cycler PERSONAL for thirty cycles. The first cycle consisted of 3 min of denaturation at 85°C, 3 min of annealing at 57°C and 4 min of extension; the next 29 cycles consisted of 1.5 min of denaturation at 85°C, 1.5 min of annealing at 57°C and 2 min of extension. After the last cycle, extension continued for an additional 3 min at 72°C. We designed the primers to be able to distinguish the fusion points of the chimeric genes. The different band sizes of RT-PCR products arising from chimeric genes between EWS and FLI-1, ERG, ETV, E1AF, or FEV are shown in Fig. 1 . We used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal marker. 15) The PCR products were electrophoresed on 2% agarose gel, stained with ethidium bromide and visualized under a UV lamp. Moreover, we analyzed the sizes of these products accurately using a Bioanalyzer (Agilent Technologies). Bioanalyzer detects laser fluorescence using Labotip in which capillary was included and it has about 5% of coefficient of variation.
RESULTS AND DISCUSSION
When the RT-PCR products from the six cell lines were analyzed by electrophoresis, the band was observed near the size expected in all cell lines ( Fig. 2A) . Moreover, using the Bioanalyzer distinct bands of approximately the expected size were observed (Fig. 2B) . GAPDH as an internal marker was also observed in all cell lines. The real band sizes as determined by Bioanalyzer were 332 base pairs (bp) (expected size 328 bp) for SK-N-MC, 333 bp (328 bp) for SK-N-L0, 398 bp (394 bp) for NCR-EW2, 651 bp (646 bp) for KP-EW-MS, and 438 bp (433 bp) for SC-MC-ES1 (Fig. 2) . No chimeric genes were detected for IMR-32. The difference between the expected band sizes and the real band sizes as determined by the Bioanalyzer was only 4 or 5 bp (less than 1.6% different from the real band size). Real RT-PCR product sizes were always 4 or 5 bp longer than expected RT-PCR product sizes.
As shown in Fig. 1 , in clinical tumor samples from ESFT, 6 different chimeric genes were detected for EWS-FLI1, 3 for EWS-ERG, 2 for EWS-FEV, and 1 each for EWS-E1AF and EWS-ETV1. All chimeric genes had different expected sizes of RT-PCR products. We can detect almost all chimeric gene RT-PCR products by Bioanalyzer because they differ by only 4 or 5 bp from the expected RT-PCR products. For instance, it is possible to distinguish the difference in about 20 bp between EWS (exon 10)-FLI1 (exon 8) (454 bp) and EWS (exon 7)-ERG (exon 6) (433 bp), which are probably undistinguishable on the gel. However, there is only a 3 bp difference between the RT-PCR products for EWS (exon 7)-ERG (exon 7) (364 bp) and EWS (exon 7)-FEV (exon 2) (361 bp), so it is difficult to distinguish between these chimeric genes by Bioanalyzer. Reliable differentiation of these RT-PCR products will require direct sequencing.
It has been reported that in the clinical tumor samples 85% of chimeric genes originated from EWS and FLI-1, 10% originated from EWS and ERG, and less than 2% each originated from EWS and E1AF, ETV1, or FEV. 16) In practice, distinguishing between the RT-PCR products for EWS (exon 7)-ERG (exon 7) (364 bp) and for EWS (exon 7)-FEV (exon 2) (361 bp) may not be a major problem, because the frequencies of both products are very low in the clinical tumor samples.
Therefore, we found that we could quickly detect in a single step almost all the specific chimeric genes in ESFT by using a mixture of primers. In the future, we will apply this method to detect the existing of living tumor cell in tumor specimen at second look operation and the diagnosis of ESFT for clinical samples from biopsies and operation. Moreover, we can also apply this method to the detection of tumor cell contamination in bone marrow and peripheral blood stem cells during autologous bone marrow transplantation and autologous peripheral blood stem cell transplantation.
It is reported that the patients with translocation at EWS (exon 7)-FLI1 (exon 6) exhibit a good prognosis. 17) Therefore, our method can be useful for the estimation of prognosis for ESFT patients too. 
